Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

22 novembre 2018

09:59
Buvidal®?is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents Camurus announced today that the European Commission has granted marketing authorisation for Buvidal® (CAM2038), the...

06:12
Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of opioid dependence in adults and adolescents from 16 years of age. This marks the first approval...

02:00
- Application based on results of pivotal phase 3 QuANTUM-R study of quizartinib in patients with relapsed/refractory FLT3-ITD AML and follows recent Breakthrough Therapy designation received from the U.S. Food and Drug Administration (FDA) -...


21 novembre 2018

18:39
Mercaptor Discoveries, a pharmaceutical company focused on developing unprecedented technology addressing significant unmet medical needs, today announced the publication of its patent application WO 2018/200527 A1, "Use of thiol compounds to treat...

16:05
Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies for the treatment of cancers, hepatitis B and aging-related diseases, announced today that the Company will present clinical data of...

14:14
AbbVie , a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or...

10:00
Blueberry Therapeutics Limited ("Blueberry Therapeutics"), a modern drug discovery and development company committed to the development of innovative new therapies for the treatment of common and difficult to treat dermatological disorders, today...

10:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for quizartinib for the treatment of adult patients with...

09:45
New research from Sheppard Pratt Health System, performed in collaboration with researchers at Johns Hopkins and the Broad Institute, shows that individuals with schizophrenia have increased levels of antibodies to the Epstein-Barr virus (EBV), a...

09:39
Kolon TissueGene, Inc. ("the Company"), a leader in advanced cell and gene therapies, announced today that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee...

09:30
Pulmatrix, Inc. announced the results of the completed first-in-human study of Pulmazole (PUR1900) ? an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in...

07:00
Synthetic Biologics, Inc. , a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the...

02:48
Medivir AB  today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. AML arises from cells in the bone marrow that are supposed to develop into...


20 novembre 2018

15:49
Locaux américains de PCS Inc. à Long Island homologués et opérationnels  Dans le cadre de son projet d'expansion internationale, Pilatus Comparator Solutions a annoncé l'homologation et la mise en service de ses locaux américains de Long Island....

12:53
PCS Inc. Long Island US Facility fully licenced and operational As part of Pilatus Comparator Solutions' ongoing plans to strengthen its Global footprint, the company has announced that their Long Island US Facility is now fully licenced and...

12:53
PCS Inc. Long Island US Facility fully licenced and operational As part of Pilatus Comparator Solutions' ongoing plans to strengthen its Global footprint, the company has announced that their Long Island US Facility is now fully licenced and...

10:00
The Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), has awarded a total of $7 million in first-round "New Therapies Challenge" grants to seven teams of top cancer researchers to...

09:16
Wize Pharma, Inc. a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome...

09:00
World Institute of Kimchi, which discovers and promotes kimchi's scientific excellence announces that the team led by Doctor Choi Hak-jong at the World Institute of Kimchi discovered Lactobacillus sakei...

08:32
AbbVie , a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upcoming 60th ASH Annual Meeting &...

08:30
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and...

08:30
TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. Gilead is the sixth partner in TARGET-NASH, joining...

08:00
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the...

07:30
Allergan plc today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam), seeking to expand the label to include the...

07:30
ProMIS Neurosciences, Inc. ; , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated year-to-date...

07:30
ProMIS Neurosciences, Inc. ; , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated year-to-date...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company's novel...

07:00
Synthego, the leading provider of genome engineering products, and Eurofins Genomics, a global leader in bioanalytical testing, announced a groundbreaking partnership today. Through this agreement, Eurofins will distribute Synthego's synthetic single...

06:13
Vitamin World, a leading specialty brand for health products in the United States, announced today a new joint antioxidant research initiative with Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital affiliated with Harvard Medical...

05:30
DelMar Pharmaceuticals, Inc. ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the...

05:00
MRI brain scans perform better than common clinical tests at predicting which people will go on to develop Alzheimer's disease, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA)....

03:00
Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias  Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative...

03:00
Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias  Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative...


19 novembre 2018

18:21
The Bonnie J. Addario Lung Cancer Foundation (ALCF) recognized outstanding contributors in research, treatment and caregiving at its Simply the Best Dinner and Gala, which took place in San Francisco on Saturday, November 9. The annual event is a...

17:47
Machavert Pharmaceuticals received funding as part of the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries (AI) Accelerator Grant Program. A committee comprised of business, technology and finance experts,...

17:30
Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci....

10:07
IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from...

10:04
Northwest Biotherapeutics -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain...

09:00
Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced it will present new data in Acute Myeloid Leukemia (AML) research at the 60th American Society of Hematology (ASH) Annual Meeting, taking place...

09:00
Cephalalgia, the official peer-reviewed medical journal of the International Headache Society, has just published positive results of the American multicentric clinical trial ACME (ACute Migraine therapy with External trigeminal neurostimulation:...

08:00
DURECT Corporation  today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents.  The Company recently...

08:00
Genomic Health, Inc. today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score® test at the 2018 San Antonio Breast Cancer Symposium® (SABCS), which will be held December 4-8. The study findings...

07:45
Dr. Axel Hofmann, a trustee of the International Foundation for Patient Blood Management, recently spoke at the U.S.-China Health Summit held in Beijing, China, from October 12-14, 2018. Initiated by Yuanli Liu, Director of 'Harvard China...

07:12
Not intended for UK-based media    Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of...

05:00
A shoulder muscle that appears unusually bright on ultrasound may be a warning sign of diabetes, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Ultrasound is commonly used to...


18 novembre 2018

23:54
CStone Pharmaceuticals (CStone) today announced that a first patient has been enrolled and dosed in a Phase I clinical trial in China for the recombinant humanized anti-programmed death-1 (PD-1) monoclonal antibody (mAb) CS1003. This multi-center...


16 novembre 2018

17:35
Aquestive Therapeutics, Inc. today announced it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for tadalafil oral film (OF). Tadalafil is a PDE5 inhibitor...

17:28
A 'first' as far as CBD bioaccessibility research goes, using the same scientifically proven method many pharmaceutical companies use, the TIM-1 test is a dynamic model of the upper gastrointestinal tract simulating fasted state conditions. Results...

14:42
AIVITA Biomedical announced today that it has dosed the first two patients in its Phase 2 clinical trial in patients with newly diagnosed glioblastoma. The trial is designed to investigate AIVITA Biomedical's next-generation patient-specific cancer...

11:44
Auritec Pharmaceuticals, Inc. ("Auritec"), a drug delivery company, announced today the completion of recruitment of its investigational product (SR-TAC), for the prophylaxis of organ transplant rejection.  SR-TAC is a novel formulation of the...